Literature DB >> 28070999

Inhibitory effect of Shenqi Fuzheng injection combined with docetaxel on lung cancer cells.

Bo-Yu Dong1, Cheng Wang1, Li Tan1, Ning Tan1, Meng-di Zhao1, Yang Lu1, Shou-Ying Du1.   

Abstract

This study investigated the anticancer effect of Shenqi Fuzheng (SQFZ) injection combined with docetaxel on lung cancer cell lines of A549 and Lewis lung cancer (LLC). SQFZ injection alone cannot inhibit the vitality of lung cancer cells, but the antitumor activity of SQFZ combined with docetaxel was significantly higher than that using docetaxel alone.

Entities:  

Keywords:  Shenqi Fuzheng injection; Docetaxel; Lung cancer cell; Inhibition ratio

Mesh：

Substances：

Year:  2017        PMID： 28070999      PMCID： PMC5260480          DOI： 10.1631/jzus.B1600357

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN： 1673-1581            Impact factor:   3.066


  4 in total

Review 1.  An overview of lung cancer genomics and proteomics.

Authors:  Courtney A Granville; Phillip A Dennis
Journal:  Am J Respir Cell Mol Biol       Date:  2005-03       Impact factor: 6.914

Review 2.  Paclitaxel and docetaxel in the treatment of breast cancer.

Authors:  Emmanouel Saloustros; Dimitris Mavroudis; Vassilis Georgoulias
Journal:  Expert Opin Pharmacother       Date:  2008-10       Impact factor: 3.889

3.  Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

Authors:  R Bruno; D Hille; A Riva; N Vivier; W W ten Bokkel Huinnink; A T van Oosterom; S B Kaye; J Verweij; F V Fossella; V Valero; J R Rigas; A D Seidman; B Chevallier; P Fumoleau; H A Burris; P M Ravdin; L B Sheiner
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

4.  [Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1].

Authors:  Wenying Zhang; Weimin Zhang; Lin Wang; Jingxian Zheng; Feng Xiao
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-05
  4 in total
  5 in total

1.  Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations.

Authors:  Jia-Li Wang; Chuan-Sheng Chen; Zhi-Rong Jia; Li-Yun Miao; Jun Xie; Zhen-Zhen Pan; Ya-Lei Duan; Shuo Liu; Meng-Jun Hou; Xuan-Sheng Ding
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-26       Impact factor: 4.322

2.  Network Pharmacology-Based identification of pharmacological mechanism of SQFZ injection in combination with Docetaxel on lung cancer.

Authors:  Tan Li; Zhu Baochen; Zhang Yue; Wang Cheng; Wu Yali; Sun Zongxi; Zhang Wantong; Lu Yang; Du Shouying
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

3.  Isorhamnetin inhibited migration and invasion via suppression of Akt/ERK-mediated epithelial-to-mesenchymal transition (EMT) in A549 human non-small-cell lung cancer cells.

Authors:  Wei Luo; Qingbin Liu; Nan Jiang; Mingquan Li; Li Shi
Journal:  Biosci Rep       Date:  2019-09-20       Impact factor: 3.840

4.  A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients.

Authors:  Qing Liu; Yanni Lou; Liya Li; Guowang Yang; Huijuan Cui; Zhiqiang Cheng; Yuan Li; Meng Liu; Chao Deng; Donggui Wan; Yongxia Yan; Liqun Jia
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.279

5.  Yangyin Fuzheng Decoction enhances anti-tumor efficacy of cisplatin on lung cancer.

Authors:  Dongmei Wei; Lin Wang; Yuhan Chen; Gang Yin; Mei Jiang; Rui Liu; Hong Chen; Xiyuan Sun
Journal:  J Cancer       Date:  2018-04-12       Impact factor: 4.207
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.